[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin Huanhu Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":420},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,78,107,136,159,180,202,228,255,282,304,329,350,374,395],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642440","temporal-interference-stimulation-treatment-in-patients-with-cognitive-impairment-100642440",false,"NCT07643363","Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","A Randomized, Sham-Controlled Trial of Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","TIS","Inclusion Criteria:\n\n* meets the criteria for probable AD and MCI due to AD as defined by the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines;\n* Positive amyloid biomarker (amyloid PET or CSF tTau\u002FAβ 42);\n* Positive tau biomarker (tau-PET or CSF pTau181);\n* AD-related standard treatments (acetyl cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists) taken at a stable dose for at least 12 weeks prior to baseline.\n* meets the criteria for probable bvFTD as defined by the revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011), or PPA as defined by the Classification of primary progressive aphasia and its variants (2011);\n* Optional genetic confirmation of FTD-related pathogenic mutations (if available).\n* Aged between 45 and 85 years, inclusive; no gender limitation.\n* Right-handed.\n* Education level ≥ 3 years.\n* Mini-Mental State Examination (MMSE) score ≥ 11.\n* Clinical Dementia Rating (CDR) score of 1 or 2.\n* with a reliable caregiver\n* Able to cooperate with cognitive assessments and cognitive training procedures.\n* Full understanding of the study, voluntary participation, and provision of written informed consent approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Diagnosis of other types of dementia or major neurological disorders (e.g., stroke, epilepsy, Lewy body dementia, vascular dementia, Parkinson's disease dementia, Huntington's disease).\n* Major psychiatric disorders such as severe depression or anxiety.\n* Severe systemic or organ dysfunction (e.g., heart failure III-IV, liver cirrhosis, renal failure).\n* Use of medications that significantly affect cognition (e.g., anticholinergics, sedatives), unless approved by the physician.\n* Presence of metal implants incompatible with MRI or TIS (e.g., pacemakers, deep brain stimulators).\n* Skull defects or cranial abnormalities.\n* Inability to tolerate EEG or head stabilization.\n* Severe visual or hearing impairment preventing task performance.\n* History of alcohol or drug abuse.\n* Participation in another clinical trial within the past 3 months.\n* Current or recent treatment with anti-amyloid monoclonal antibodies (e.g., lecanemab, donanemab).","ALL","45 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the efficacy and safety of temporal interference stimulation (TIS), a non-invasive neuromodulation technique, in improving cognitive function in patients with cognitive impairment. TIS uses two high-frequency currents applied transcranially, which intersect within the brain to generate a low-frequency modulation field. This technique selectively modulates deep brain regions while minimizing the stimulation of superficial cortical layers.\n\nParticipants will undergo individualized MRI-based modeling to determine the optimal electrode placement and stimulation parameters. The intervention consists of 10 stimulation sessions over a period of 14 days, using either active TIS or sham stimulation. Cognitive assessments, EEG recordings, and functional MRI scans will be conducted at baseline; 5 days after intervention initiation; at the end of the 10-day intervention; and during follow-up assessments at 4 weeks, 8 weeks, and 12 weeks post-intervention to evaluate both immediate and long-term effects on cognitive performance and neural activity.\n\nThe study aims to determine whether TIS can serve as a feasible and effective neuromodulation strategy for individuals with cognitive impairment.",[28,29,30,31],"Amnestic Mild Cognitive Impairment - aMCI","AD-MCI","AD - Alzheimer's Disease","FTD",[33,34,35],"Temporal Interference Stimulation","Alzheimer's Disease","Frontotemporal Dementia","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":22},"2026-07-01",{"date":44,"type":22},"2029-06",{"name":46,"class":47},"Tianjin Huanhu Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100622622","etiology-phenotype-outcome-pathway-study-on-freezing-of-gait-fog-100622622","NCT07386015","Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","FREEZE-Path Cohort: Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","Inclusion Criteria:\n\n1. Age 30-85 years\n2. Presence of freezing of gait or non-freezing gait or balance impairment\n3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus)\n4. Ability to complete gait and balance assessment tasks independently or with assistance\n5. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe dementia (Mini-Mental State Examination score \\\u003C 10)\n2. Severe psychiatric disorders interfering with study participation\n3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety\n4. Stroke, fracture, or other major medical events within the past 3 months\n5. Inability to comply with follow-up procedures\n6. Refusal of video or speech data collection","30 Years",{"count":58,"type":22},700,"36 Months","OBSERVATIONAL","This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.",[63,64,65,66,67],"Freezing of Gait","Parkinson's Disease","Parkinsonism","Vascular Parkinsonism","Idiopathic Normal Pressure Hydrocephalus (INPH)",[63,64,69],"parkinsonism","2026-03-08",{"date":72,"type":40},"2026-03-10",{"date":74,"type":40},"2026-02-28",{"date":76,"type":22},"2030-11-30",{"name":46,"class":47},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100623122","early-phase-1-universal-chimeric-antigen-receptor-t-cell-ucar-t-cell-therapy-targeting-cd19-bcmaqt-019c-in-patients-with-r-r-neurological-autoimmune-diseases-100623122","NCT07392528","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002F BCMA（QT-019C） in Patients With r\u002F r Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA（QT-019C） in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years. The following conditions are excluded: non-melanoma skin cancer, stage I tumors that have a low recurrence probability after complete resection, clinically localized prostate cancer after treatment, cervical carcinoma in situ confirmed by biopsy or squamous intraepithelial lesion shown on smear, stable papillary thyroid carcinoma or follicular thyroid carcinoma.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.","18 Years",{"count":87,"type":22},15,[89],"EARLY_PHASE1","This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells（QT-019C）.",[92,93,94],"Neuromyelitis Optica Spectrum Disorders","Multiple Sclerosis","Myasthenia Gravis",[96,97],"Universal Allogeneic CAR T-cells","QT-019C","NOT_YET_RECRUITING","2026-02-08",{"date":101,"type":40},"2026-02-11",{"date":103,"type":22},"2026-03",{"date":105,"type":22},"2028-12",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100621042","phase-2-efficacy-and-safety-of-intra-arterial-albumin-as-adjunct-to-mechanical-thrombectomy-in-acute-ischemic-stroke-100621042","NCT07365475","Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)","AMASS2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute anterior circulation large vessel occlusion (including ICA\u002FMCA-M1 tandem occlusion or isolated MCA-M1 occlusion) confirmed by CTA, MRA, or DSA, with successful recanalization (eTICI score ≥2b) confirmed by the final intraoperative DSA following mechanical thrombectomy\n* Baseline NIHSS scores ≥ 6\n* Non-contrast CT ASPECTS ≥6\n* Time from stroke onset (or last known well) to arterial puncture within 24 hours\n* Pre-stroke functional independence, defined as a modified Rankin Scale (mRS) score \\\u003C2\n* Written informed consent obtained from the patient or a legally authorized representative\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by cranial CT or MRI\n* Midline shift with significant mass effect on cranial CT or MRI\n* Isolated internal carotid artery (ICA) occlusion\n* History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension or pericardial effusion\n* Hemodynamically unstable arrhythmia (based on patient self-report or detected prior to infusion)\n* Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission\n* Acute or chronic renal failure (serum creatinine \\>2.0 mg\u002FdL\n* Severe anemia (hematocrit \\\u003C32%\n* Known hypersensitivity to albumin or blood products\n* Pregnancy\n* Persistent hypertension (blood pressure ≥180\u002F100mmHg) prior to albumin infusion\n* Current participation in other clinical trials\n* Life expectancy of less than 3 months\n* Concomitant severe pulmonary disease, such as chronic obstructive pulmonary disease, pulmonary fibrosis, pleural effusion, or acute respiratory distress syndrome\n* Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in the study",{"count":116,"type":22},306,[118],"PHASE2","Stroke remains a predominant global public health challenge, ranking as the third leading cause of death and the fourth leading contributor to disability-adjusted life years (DALYs). According to the Global Burden of Disease Study 2021, there are approximately 93.8 million prevalent stroke cases and 11.9 million new cases worldwide. China bears one of the heaviest burdens, with over 2 million new cases annually. Acute ischemic stroke (AIS), caused by acute cerebrovascular occlusion, accounts for 80% of all strokes. Approximately 30% of AIS cases result from large vessel occlusion (LVO), which typically carries a poor prognosis due to the extensive area of infarction . Research indicates that early recanalization significantly improves clinical outcomes. Currently, intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard treatments for achieving recanalization . For LVO-related AIS, MT has become the preferred clinical approach due to its extended therapeutic window and superior recanalization rates . However, despite successful recanalization in over 70% of patients, nearly 50% fail to achieve functional independence at 90 days, and mortality remains above 15% . Therefore, enhancing long-term functional outcomes in post-MT patients is a critical unmet clinical need. Human albumin is the most abundant protein in plasma. Beyond maintaining colloid osmotic pressure, it also possesses multiple biological effects, including anti-inflammatory, anti-platelet aggregation, antioxidant, and endothelial protective properties. We conducted a Phase I clinical trial (AMASS-1) for patients post-mechanical thrombectomy, administering human albumin via the internal carotid artery. The results showed that intra-arterial infusion of 20% human albumin at a dose of 0.60 g\u002Fkg was safe, with no significant differences in serious adverse reactions such as mortality \\[Albumin group (6.7%) vs Control group (6.7%), P \\> 0.05\\] and symptomatic intracranial hemorrhage \\[Albumin group (6.7%) vs Control group (13.3%), P \\> 0.05\\] compared to the control group. In summary, albumin adjunctive therapy demonstrates good safety and potential neuroprotective effects in patients after mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we plan to conduct a Phase II clinical trial of mechanical thrombectomy combined with intra-arterial albumin infusion for acute ischemic stroke. This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the efficacy and safety of intra-arterial infusion of 20% human serum albumin combined with mechanical thrombectomy versus mechanical thrombectomy alone in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who have achieved recanalization after mechanical thrombectomy. A total of 306 patients are planned to be enrolled and randomly assigned in a 1:1 ratio using a dynamic minimization method to two groups: the Albumin Group (0.6 g\u002Fkg 20% human serum albumin plus Mechanical Thrombectomy) and the Control Group (Mechanical Thrombectomy alone). The primary efficacy objective of this study is to evaluate whether immediate intra-arterial infusion of 20% human albumin (0.6 g\u002Fkg) via the internal carotid artery following successful recanalization (eTICI ≥2b) improves clinical outcomes in patients with acute anterior circulation large vessel occlusion stroke, compared with mechanical thrombectomy alone. The study also aims to evaluate the safety and feasibility of immediate intra-arterial infusion of 20% human albumin (0.6 g\u002Fkg) via the internal carotid artery in patients with acute anterior circulation large vessel occlusion stroke who have achieved successful recanalization (eTICI ≥2b) following standard mechanical thrombectomy.",[121],"Acute Ischemic Stroke From Large Vessel Occlusion",[123,124,125,126,127],"acute ischemic stroke","large vessel occlusion","mechanical thrombectomy","albumin","neuroprotection","2026-01-16",{"date":130,"type":40},"2026-01-26",{"date":132,"type":22},"2026-01-30",{"date":134,"type":22},"2028-08-30",{"name":46,"class":47},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":48},"100588266","early-phase-1-universal-chimeric-antigen-receptor-t-cell-ucar-t-cell-therapy-targeting-cd19b-cell-maturation-antigen-cd19bcma-in-patients-with-rr-neurological-autoimmune-diseases-100588266","NCT06939166","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002FB Cell Maturation Antigen （CD19\u002FBCMA） in Patients With r\u002Fr Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.",{"count":144,"type":22},12,[89],"This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells.",[92,94,93,148,149],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Autoimmune Encephalitis",[96],"2025-12-11",{"date":153,"type":40},"2025-12-15",{"date":155,"type":40},"2025-06-17",{"date":157,"type":22},"2027-10",{"name":46,"class":47},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100615575","phase-2-the-preliminary-efficacy-and-safety-of-intra-arterial-albumin-as-adjunct-to-mechanical-thrombectomy-in-acute-ischemic-stroke-100615575","NCT07294391","The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke：Dual-Center, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* 1.Age ≥ 18 years; 2.ICA or MCA-M1 occlusion, confirmed by preoperative CTA\u002FMRA\u002FDSA. ICA occlusion can be cervical or intracranial, with or without tandem MCA lesions; Treated with EVT resulting in recanalization ((expanded Thrombolysis in Cerebral Infarction \\[eTICI\\] 2b-3); 3.Baseline NIHSS scores ≥ 6; 4.Baseline ASPECTS ≥6 on non-contrast CT; 5.The time from stroke onset\u002Flast seen well to arterial puncture is within 24 hours; 6.No significant pre-stroke disability (pre-stroke mRS ≤2); 7.Signed informed consent from the patient or the legally authorized representative\n\nExclusion Criteria:\n\n* 1.Presence of intracranial hemorrhage on head CT or MRI； 2.Midline shift with significant mass effect on head CT or MRI； 3.History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension, pericardial effusion, etc； 4.Arrhythmia accompanied by hemodynamic instability； 5.Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission； 6.Acute or chronic renal failure (serum creatinine \\>2.0 mg\u002FdL)； 7.Severe anemia (hematocrit \\\u003C32%)； 8.Known allergy to albumin or blood products； 9.Pregnant women； 10.Persistent blood pressure ≥180\u002F100 mmHg prior to albumin infusion； 11.Concurrent participation in another clinical trial； 12.Life expectancy of less than 3 months； 13.Coexisting severe pulmonary diseases such as Chronic Obstructive Pulmonary Disease, pulmonary fibrosis, pleural effusion, pulmonary hypertension, or acute respiratory distress syndrome； 14.Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study.",{"count":21,"type":22},[118],"Albumin-assisted therapy has demonstrated good safety and potential neuroprotective effects following mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we are conducting a Phase IIa clinical trial of intra-arterial albumin administration combined with mechanical thrombectomy in patients with acute ischemic stroke. This is a double-center, prospective, open-label, endpoint-blinded, randomized controlled trial designed to preliminarily assess the efficacy and safety of intra-arterial infusion of 20% human albumin after successful recanalization in patients with acute ischemic stroke caused by anterior circulation large-vessel occlusion who undergo mechanical thrombectomy. A total of 60 patients will be enrolled and randomized in a 1:1 ratio by dynamic minimization into two groups: the albumin group (0.6 g\u002Fkg of 20% human albumin solution plus mechanical thrombectomy) and the control group (mechanical thrombectomy alone).\n\nThe primary objective of this study is to preliminarily evaluate whether intra-arterial infusion of 0.6 g\u002Fkg of 20% human albumin via the internal carotid artery immediately after achieving successful recanalization (eTICI ≥ 2b) can reduce infarct volume compared with mechanical thrombectomy alone in patients with anterior circulation large-vessel occlusion who undergo standard mechanical thrombectomy. The secondary objective is to assess the safety and feasibility of intra-arterial infusion of 0.6 g\u002Fkg of 20% human albumin immediately after successful recanalization in this patient population.",[121],[171,124,125,126,127],"Acute ischemic stroke","2025-12-07",{"date":174,"type":40},"2025-12-19",{"date":176,"type":22},"2025-12-10",{"date":178,"type":22},"2026-12-01",{"name":46,"class":47},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":48},"100601823","combined-recanalization-therapy-for-acute-large-vessel-occlusion-stroke-100601823","NCT07115511","Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke","CRTALVOS","Inclusion Criteria:\n\n1. Age: 18-75.\n2. According to the current guidelines, there is a MT indication.\n3. Before stroke, mRS ≤2;\n4. ASPECTS ≥6;\n5. MCA occlusion, with or without ICA occlusion;\n6. MT unsuccessful, TICI score 0-1;\n7. Time from onset to craniotomy expected to be 24 hours or less;\n8. Post-awakening stroke with mismatch between the infarct zone and the penumbra zone;\n\nExclusion Criteria:\n\n1. Comorbid hemorrhagic vascular disease such as intracranial aneurysm or vascular malformation or other planned cerebrovascular surgery that may alter cerebral hemodynamics or lead to stroke;\n2. unstable angina or myocardial infarction, congestive heart failure within the previous 6 months;\n3. Pregnancy or perinatal period;\n4. Hematologic disorders resulting in coagulation disorders;\n5. Combination of other diseases with a life expectancy of less than 2 years; and\n6. previous treatment with intracranial or extracranial vascular bypass surgery;\n7. allergy to iodine or X-ray contrast media, creatinine \\>3.0 mg\u002Fdl or other contraindications to arteriography;\n8. Uncontrolled diabetes mellitus, fasting blood sugar (FBS) \\>16.7 mmol\u002FL;\n9. Uncontrolled hypertension with sitting systolic blood pressure \\>180 mmHg or sitting diastolic blood pressure \\>110 mmHg;\n10. Severe hepatic dysfunction, defined as serum alanine aminotransferase (ALT) and\u002For alanine aminotransferase (AST) \\>3 times the upper limit of normal;\n11. Platelets \\\u003C100×109 \u002FL.\n12. Received a clinical trial drug or device within 30 days prior to screening, or is participating in another clinical trial;\n13. contraindication to general anesthesia or craniotomy;\n14. other diseases or medical history that, in the investigator's judgment, may affect the efficacy or safety evaluation of this study.","75 Years",{"count":189,"type":22},64,[25],"The purpose of this clinical trial is to evaluate the efficacy and safety of combined recanalization therapy in patients who cannot be recanalized by acute large vessel occlusive stroke. The main questions it aims to answer are:\n\n1、Proportion of subjects with mRs score of 0-1 at 90 days after surgery\n\nParticipants will:\n\n1、In acute large vessel occlusive stroke, if traditional means cannot be recanalized, combined recanalization surgery (including arteriotomy and thrombectomy, cerebrovascular bypass surgery) is performed.",[193],"Stroke","2025-08-04",{"date":196,"type":40},"2025-08-11",{"date":198,"type":40},"2024-12-01",{"date":200,"type":22},"2026-11-30",{"name":46,"class":47},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":48},"100563819","a-real-world-study-of-tenecteplase-versus-alteplase-for-thrombolysis-in-patients-within-45-h-of-onset-of-ischemic-stroke-100563819","NCT06621121","A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke","Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke : a Multicenter, Prospective, Observational, Real-world Study（TRANSIT）","TRANSIT","Inclusion Criteria:\n\n\\- 1. Symptoms of neurological deficit caused by ischemic stroke; 2. The time from onset to treatment ≤4.5 hours; The time of onset of symptoms was defined as the time of last seen normal.\n\n3\\. Age ≥18 years old; 4. Signed informed consent by patients or their legally authorized representative.\n\nExclusion Criteria:\n\n* 1\\. Any absolute contraindication to thrombolysis in the \\"Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023\\" 2.Allergy to TNK or alteplase 3.Participation in another clinical trial within the previous 3 months. 4.Other conditions deemed inappropriate for participation in this study.",{"count":211,"type":22},6000,"Stroke is the second leading cause of death worldwide, killing nearly 7 million people every year. Acute ischemic stroke is caused by focal cerebral hypoperfusion, usually due to embolism or atherosclerotic disease . Ischemic strokes account for 60-70% of all strokes worldwide and are severely debilitating, drawing considerable attention due to their high prevalence.The majority of studies comparing the efficacy and safety of teneplase and alteplase are predominantly randomized controlled trials with limited representation from real-world studies.The aim of this study is to compare the safety, efficacy and economic benefits of recombinant human TNK tissue plasminogen activator (tenecteplase, rhTNK-tPA, TNK) and recombinant tissue plasminogen activator (alteplase, rtPA) in clinical practice. This study aimed to establish a foundation for refining intravenous thrombolytic therapy tailored to various patient profiles and to guide clinicians in selecting the most suitable thrombolytic treatment options.",[214,215,216],"Stroke Acute","Tenecteplase","Alteplase",[218,219,220],"ischemic stroke","tenecteplase","alteplase","2024-10-26",{"date":223,"type":40},"2024-10-29",{"date":221,"type":22},{"date":226,"type":22},"2026-10-01",{"name":46,"class":47},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":243,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":48},"100566376","thrombectomy-versus-best-medical-management-in-large-vessel-occlusion-stroke-patients-presenting-beyond-24-hours-and-with-presence-of-collateral-flow-on-ct-angiography-100566376","NCT06654375","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography: A Multicentre, Open-label, Registry-linked, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Confirmation of ICA or MCA-M1 occlusion, as detected by MRA or CTA, with carotid occlusions potentially occurring in either the cervical or intracranial regions, and the possibility of accompanying tandem MCA lesions.\n2. Demonstration of moderate to good collateral flow, as evidenced by CTA imaging.\n3. The patient must be aged 18 years or older.\n4. The baseline NIHSSS score is equal to or greater than 2, and this score remains equal to or greater than 2 immediately prior to randomization.\n5. Endovascular treatment can be initiated (via femoral puncture) within a window of 24 to 72 hours from the onset of the stroke. The onset of the stroke is defined as the time the patient was last known to be at their neurologic baseline (patients with wake-up strokes are eligible if they meet the aforementioned time constraints).\n6. There must be no significant pre-stroke disability, as indicated by a pre-baseline modified Rankin Scale score of 0-2.\n7. The patient must be willing and able to return for the protocol-required follow-up visits.\n8. The patient or their legally authorized representative must have signed the Informed Consent form.\n\nExclusion Criteria:\n\n1. The subject has a serious, advanced, or terminal illness (as determined by the investigator) or a life expectancy of less than six months.\n2. The subject has a pre-existing medical, neurological, or psychiatric disease that would interfere with neurological or functional evaluations, or is already participating in another drug or device study.\n3. The subject is pregnant.\n4. The subject has contraindications for both MRI and CT contrast that prevent an MRI or CT contrast perfusion study. The hospital's local standard criteria should be applied to determine if contraindications exist.\n5. The subject has a known allergy to iodine and has previously been refractory to pretreatment medications.\n6. The subject has been treated with tPA more than 4.5 hours after the last known well time.\n7. The subject has a known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or has recently undergone oral anticoagulant therapy with an INR greater than 3.\n8. The subject has symptoms consistent with stroke in multiple locations.\n9. The subject has seizures at stroke onset, which makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.\n10. The subject has a baseline blood glucose level of less than 50mg\u002FdL (2.78 mmol) or greater than 400mg\u002FdL (22.20 mmol).\n11. The subject has a baseline platelet count of less than 50,000\u002FuL.\n12. The subject has severe, sustained hypertension (Systolic Blood Pressure \\>185 mmHg or Diastolic Blood Pressure \\>110 mmHg) that is not treatable with medications.\n13. The subject is currently participating in another investigational drug or device study or registry.\n14. The subject is presumed to have a septic embolus, suspicion of bacterial endocarditis, or cerebral vasculitis.\n15. The subject has had clot retrieval attempted using a neurothrombectomy device within 24 hours of symptom onset.",{"count":236,"type":22},350,[25],"The goal of this clinical trial is to investigate if endovascular treatment (EVT) can effectively treat patients with large vessel occlusion (LVO) who present beyond the typical 24-hour window after symptom onset. The main questions it aims to answer are:\n\n* Can EVT improve functional independence at 90 days for patients treated after 24 hours?\n* What is the safety profile of EVT in this delayed treatment group compared to best medical management (BMM)? Researchers will compare EVT outcomes in patients presenting after 24 hours to those receiving BMM to see if EVT offers significant benefits.\n\nParticipants will:\n\n* Receive either EVT or BMM based on their eligibility.\n* Undergo CT angiography to assess collateral circulation and to confirm the presence of LVO.\n* Be followed for 90 days to evaluate functional outcomes and safety measures.",[214,240,241,242],"Thrombectomy","Medical Treatment","Large Vessel Occlusion",[244,245,246],"CTA","Endovascular Thrombectomy","Acute Ischemic Stroke","2024-10-22",{"date":249,"type":40},"2024-10-23",{"date":251,"type":40},"2024-06-25",{"date":253,"type":22},"2027-12-31",{"name":46,"class":47},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":48},"100495753","patient-selection-using-mr-with-non-perfusion-imaging-for-endovascular-treatment-within-6-to-24-hours-100495753","NCT05735301","Patient Selection Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours","Patient Selection Based on Penumbra-core Mismatch Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours: Rationale and Trial Design","MIELS","Inclusion Criteria:\n\n* Age of 18 years or older；\n* Anterior circulation LVO (internal carotid artery, or middle cerebral arteries (MCA)M1, M2 proximal segment) confirmed by computed tomographic angiography (CTA)\u002Fmagnetic resonance angiography (MRA)；\n* NIHSS score ≥6 at the time of randomization；\n* ASPECTS score ≥ 6 on NCCT；\n* Time from stroke onset to randomization within 6-24 hours；\n* Pre-stroke mRS score 0-2；\n* Completed MRI and perfusion imaging or enable to complete MRI and\u002For perfusion imaging；\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy, or those potential with positive urine or serum beta Human Chorionic Gonadotrop in test；\n* A history of severe allergy to contrast media；\n* Uncontrolled hypertension (SBP \\>185mmHg; DBP\\>110mmHg)；\n* Hereditary or acquired bleeding tendency, coagulation factor deficiency, recent anticoagulant medication (A platelet count of less than 100 x 109 \u002FL；INR\\>3 or PPT more than 3 times normal)；\n* Active hemorrhage or preexisting tendency to hemorrhage；\n* Presence of signs of cardiac, hepatic or renal failure；\n* Baseline blood glucose\\\u003C50mg\u002FdL (2.78mmol) or \\>400mg\u002FdL (22.20mmol)；\n* Participation in other interventional randomized clinical trials that may confound the outcome assessment of the trial；\n* Life expectancy \\\u003C 1 year；\n* Patients who are unable to complete the 90-day follow-up；\n* A stroke attack with epilepsy that prevents an accurate NIHSS score from being obtained；\n* Other circumstances that the investigator considers inappropriate for participation in the trial(such as violation of guidelines or institutional processing principles during the screening process).",{"count":264,"type":22},352,[25],"We will conduct a multicenter, prospective, randomized, open-label, blinded endpoint trial with a non-inferiority design in patients who present 6 to 24 hours after symptom onset with LVO. Patients who meet eligibility criteria will be randomly assigned to the Non-perfusion or Perfusion group with a 1:1 ratio. In the Non-perfusion group, patients with penumbra-core mismatch (defined as the FLAIR Vascular Hyperintensity (FVH) extending beyond the boundary of the DWI cortical lesions) will receive EVT. In the Perfusion group, patients with perfusion mismatch (defined as regional cerebral blood flow (\\\u003C30%) \\\u003C 70 ml with mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 ml) will receive EVT. Patients in both groups will receive guideline-based medical treatment. If patients in both groups do not meet the criteria for EVT, only guideline-based medical treatment will be administered.",[245],[269,270,271,272,273],"select patients","endovascular thrombectomy","magnetic resonance imaging","CT\u002FMR perfusion","FVH-DWI mismatch","2024-06-20",{"date":276,"type":40},"2024-06-24",{"date":278,"type":40},"2019-01-01",{"date":280,"type":22},"2024-09",{"name":46,"class":47},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":48},"100531511","triage-of-patients-presenting-beyond-24-hours-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-track-lvo-late-100531511","NCT06200753","Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)","Triage of Patients Presenting Beyond 24 Hours From Last Known Well With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late): a TRACK-LVO Registry-linked Cohort","TRACK-LVO Late","Inclusion Criteria:\n\n* Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n* Presenting beyond 24 hours from last known well;\n* Ischemic stroke confirmed by head CT or MRI;\n* Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n* Patients receiving either endovascular therapy or best medical treatment.\n\nExclusion Criteria:\n\n• Presence of any forms of cerebral hemorrhage on CT\u002FMR at admission.",{"count":291,"type":22},1000,"The objective of this study is to create a comprehensive, multi-center, TRACK-LVO registry-linked cohort of consecutive patients with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO) and presenting to each participating center beyond 24 hours from last known well, who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[245,242,246],[295],"Acute Ischemic Stroke, Endovascular Therapy,","2023-12-30",{"date":298,"type":40},"2024-01-11",{"date":300,"type":40},"2018-01-01",{"date":302,"type":22},"2028-12-31",{"name":46,"class":47},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":312,"targetDuration":314,"studyType":60,"phases":4,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":328},"100489902","triage-of-patients-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-2-100489902","NCT05659160","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2 (TRACK-LVO-2): an Imaging-based Patient Registry Study","TRACK-LVO-2","Inclusion Criteria:\n\n1. Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n2. Age ≥ 18;\n3. Ischemic stroke confirmed by head CT or MRI;\n4. Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n5. Patients receiving either endovascular therapy or best medical treatment;\n\nExclusion Criteria:\n\n\\- None",{"count":313,"type":22},5000,"1 Year","The objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO), who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[317,318,242],"Stroke, Acute Ischemic","Endovascular Procedures",[246,320,242],"Endovascular Therapy","2023-11-28",{"date":323,"type":40},"2023-12-01",{"date":325,"type":40},"2021-11-01",{"date":302,"type":22},{"name":46,"class":47},4,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":328},"100523352","medical-imaging-screening-for-posterior-circulation-ischemic-stroke-100523352","NCT06094569","Medical Imaging Screening for Posterior-circulation Ischemic Stroke","Medical Imaging Screening for Posterior-circulation Ischemic Stroke：a Multicentre,Imaging-based,Prospective Cohort Study","Inclusion Criteria:\n\n1. Patient admitted from Jun. 1st 2019 to Jan. 1st 2029;\n2. Patients with acute ischemic stroke recently；\n3. Symptoms persisted at admission, and MRI (including DWI) confirmed acute ischemic vertebrobasilar artery occlusion in the posterior circulation:（single right or left intracranial branch of vertebral artery occlusion ; single basilar occlusion ; both two vertebral arterys and basilar artery）；\n\nExclusion Criteria:\n\n1.Patiens can not meet the MRI examination conditions(with absolute and relative contraindications).",{"count":291,"type":22},"Patients with ischemic stroke in the posterior circulation continue to have high rates of mortality and disability, even with aggressive treatment. We wanted to evaluate preoperative imaging to screen patients with a good prognosis from mechanical embolization. We assess the degree of ischemia by defining the pons-midbrain-medulla index (PMMI) and correlate the preoperative PMMI with the clinical prognosis of postoperative patients to verify the validity of PMMI in predicting the clinical prognosis of patients with embolization.",[245],[269,270,271,340,341],"diffusion weighted imaging","Vertebrobasilar artery","2023-10-16",{"date":344,"type":40},"2023-10-23",{"date":346,"type":40},"2019-06-01",{"date":348,"type":22},"2029-12-31",{"name":46,"class":47},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":357,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":48},"100523058","effect-and-mechanism-of-brain-stimulation-for-parkinsons-disease-with-cognitive-impairment-100523058","NCT06090682","Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment","Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment","Inclusion Criteria:\n\n1\\. The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, acute levodopa motor response ≥30%, and indication for STN-DBS.\n\nExclusion Criteria:\n\nExclusion criteria included patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery.",{"count":358,"type":22},200,"This study intends to apply structural and functional brain network neuroimaging techniques combined with image post-processing methods to explore the differences in brain network changes in PD patients with cognitive impairment after DBS or TMS.",[361,362],"Parkinson Disease","Cognitive Impairment",[361,362,364,365],"Deep brain stimulation","Transcranial magnetic stimulation","2023-10-14",{"date":368,"type":40},"2023-10-19",{"date":370,"type":22},"2023-11-01",{"date":372,"type":22},"2027-11-01",{"name":46,"class":47},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":381,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":4},"100512954","study-on-brain-network-mechanism-of-deep-brain-stimulation-for-parkinsons-disease-100512954","NCT05959161","Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's Disease","Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's （A Retrospective Study）","Inclusion Criteria:The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, age under 75, acute levodopa motor response ≥30%, and indication for STN-DBS. -\n\nExclusion Criteria: patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery -",{"count":382,"type":22},100,"As a surgical intervention, DBS can effectively relieve PD tremor, rigidity, bradykinesia and other symptoms. How to better screen patients suitable for DBS treatment and conduct reasonable preoperative and postoperative evaluation is crucial to judge the treatment effect and prognosis. The clinical symptom evaluation of PD patients can be divided into motor symptom evaluation and non-motor symptom evaluation. The motor symptoms of PD patients were evaluated by UPDRS III. The evaluation of non-motor symptoms in PD patients was mainly divided into three aspects: cognitive status, emotional status, and sleep status. Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess the cognitive status of PD patients. The Hamilton Depression Scale (HAMD) was used to assess the patients' depression status. The Hamilton Anxiety Scale (HAMA) was used to assess the patients' anxiety status. The PD Sleep Scale 2nd version, The PD Sleep Scale 2nd version, PDSS - 2), and rem Sleep Behavior Disorder Questionnaire (sweet HK) (Rapid Eye Movement Sleep behaviors Disorder Questionnaire - Hong Kong, RBDQ - HK) to assess Sleep conditions.",[361,385,386],"Deep Brain Stimulation","Non-motor Symptoms","2023-07-17",{"date":389,"type":40},"2023-07-25",{"date":391,"type":22},"2023-08-01",{"date":393,"type":22},"2026-12-31",{"name":46,"class":47},{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":402,"targetDuration":404,"studyType":60,"phases":4,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":48},"100489468","remote-ischemic-conditioning-combined-with-endovascular-stenting-for-symptomatic-intracranial-atherosclerotic-stenosis-100489468","NCT05653505","Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis","Safety and Efficacy of Remote Ischemic Conditioning Combined With Endovascular Stenting in Patients With Symptomatic Intracranial Atherosclerotic Stenosis","Inclusion Criteria:\n\n1. Patient admitted from Jan. 1st 2023 to Jan. 1st 2025;\n2. Age ≥ 18;\n3. Intracranial atherosclerosis stenosis measured as ≥70% by digital subtraction angiography or by other noninvasive methods, such as transcranial doppler, computed tomography angiography, or magnetic resonance angiography;\n4. A history of stroke\u002Ftransient ischemic attack attributed to ICAS;\n5. Verbal and written informed consent is provided at the time of admission by patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Stenosis of other causes;\n2. Prior ipsilateral stroke with residual deficits;\n3. Uncontrolled hypertension (defined as systolic blood pressure ≥200 mm Hg despite medications at enrollment);\n4. Peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion).",{"count":403,"type":22},160,"12 Months","The purpose of this registry is to evaluate the safety and efficacy of RIC for patients with symptomatic intracranial atherosclerotic stenosis (sICAS) undergoing endovascular therapy.",[407,408,318],"Intracranial Arteriosclerosis","Ischemic Preconditioning",[410,411,412],"Remote Ischemic Conditioning","Endovascular Stenting","Symptomatic Intracranial Atherosclerotic Stenosis","2022-12-15",{"date":415,"type":40},"2022-12-16",{"date":417,"type":22},"2023-01-01",{"date":42,"type":22},{"name":46,"class":47},""]